Latest Drugwonks' Blog

Tykerb is one of the newest tyrosine kinase inhibitors (TKI).  It interrupts the signaling pathway that produces a specific protein involved in the creation and support of cancer cell growth.  It is a small molecule drug that can target both HER 2 and HER 1 breast cancers.  Because it is a small molecule drug and not a large molecule it can also enter the brain where up to half of all late stage breast cancers spread.  Also, recent studies presented at the American Society of Clinical Oncology Breast Cancer Symposium on September 5, 2008. have shown that Tykerb can be used in combination with new gene profiling tests to tailor treatment to patients who would gain the most benefit and least risk:
http://community.breastcancer.org/forum/73/topic/721033

"Conclusions of the study had shown that Tykerb has antivascular activity superior to that of Nexavar. Avastin + Tykerb may be the first clinically-exploitable antivascular drug combination. High dose, intermittent 'bolus' schedules of Tykerb to coincide with Avastin administration may be clinically advantageous, even in HER2-negative tumors.

The system utilized for the study was a functional profiling assay, which may be used to individualize antivascular therapy. It can be adapted for simple, inexpensive and sensitive/specific detection of tissue and circulating microvascular cells in a variety of neoplastic and non-neoplastic conditions, for drug development, and individualized cancer treatment.

The cell-based assay can accurately sort drugs into categories of above average probability of providing clinical benefit on one hand and below average probability of providing clinical benefit on the other hand, based both on tumor response and patient survival."


And so how doth the comparative effectiveness institute known as NICE rule upon the value of Tykerb:
 

The Wall Street Journal (10/15, B2, Berton) reports, "GlaxoSmithKline PLC's breast-cancer drug Tyverb (lapatinib) shouldn't be eligible for reimbursement under the U.K.'s publicly funded healthcare system," the U.K.'s National Institute of Clinical Excellence (NICE) recommended on Tuesday. The company said that NICE, "which decides what treatments are made available free to U.K. patients, isn't recommending Tyverb's use by the National Health System. In its decision, NICE rejected the drugmaker's offer to bear part of the cost of the treatment."

        The U.K.'s Telegraph (10/14, Smith) added that "trials of the drug...have shown it can reduce the size of a tumor by 60 percent and extend life by an average of two months, compared to standard treatment." But NICE "says it does not extend life by long enough to justify the extra cost."

As long as comparative effectiveness is conducted by the payor, for the payor and of the payor, the value of personalized medicine will be in the words of the Faber College's Dean Wormer:

"Zero, point zero." 

For a look at how NiCE conducts its comparative effectiveness work, take a look at this video: 

http://www.youtube.com/watch?v=xVdUsgYA_D4

 

At yesterday’s CMPI conference on the impact government-care has on physicians (in Europe, Canada, and the US), Brian Lee Crowley (President of the Nova Scotia-based Atlantic Institute for Market Studies) offered the following comments:

In summarizing the current state of the physician within the healthcare system in Canada I sought inspiration in poetry and was drawn to a poem by Elizabeth Barrett Browning, With apologies, I have somewhat modified her poem and entitled it:

Ode to a Canadian Physician

How do I disempower thee? Let me count the ways.
I disempower thee to the depth and breadth and height
My bureaucratic soul can reach, when some aspect of the health system escapes my
control.
For the ends of cutting my costs and using thy ideal Grace to shield me from the sting of
patient discontent.
I disempower thee to the level of everyman's
Most urgent healthcare need, by sun and candle-light, which are the pinnacle of the
technological sophistication thou art allowed.
I disempower thee freely, as men strive for “free” healthcare and end by merely
restricting access to thee.
I disempower thee purely, as they turn from specialists and hospitals in despair of finding
timely treatment there.
I disempower thee with a passion put to use
In my efforts to ingratiate myself with the electorate; Thank God for their childish faith.
I disempower thee with a loss of access to medical schools, thus ensuring that many will
never know the joys of thy tender care
I disempower thee with the breath,
Smiles, tears, and above all the income of all your life! --- and, if the Minister of Health
so choose,
I shall but disempower thee better if thou hast the temerity to prescribe a drug I judge too
costly, no matter how efficacious.

To reinforce his point in somewhat less poetic terms, Brian pointed to the following story that ran in the Canadian newspaper, the National Post, on August 06, 2008

MD uses lottery to cull patient list

In the latest jarring illustration of the country's doctor shortage, a family physician in Northern Ontario has used a lottery to determine which patients would be ejected from his overloaded practice.

Dr. Ken Runciman says he reluctantly eliminated about 100 patients in two separate draws to avoid having to provide assembly-line service or extend already onerous work hours, and admits the move has divided the community of Powassan.

Yet it was not the first time such methods have been employed to determine medical service. A new family practice in Newfoundland held a lottery last month to pick its caseload from among thousands of applicants. An Edmonton doctor selected names randomly earlier this year to pare 500 people from his heavy caseload. And in Ontario, regulators have heard reports of a number of other physicians also using draws to choose, or remove, patients, limit their prescribing to the state formulary, with sometimes extremely grave consequences for their patients.

Brian’s complete remarks can be found
here.

Here is how he concluded his presentation:

Physicians surrendered great power to order their own professional lives and to act in the interests of their patients when physicians and hospital care was essentially taken under full political direction in the 1960s in a wave of ideological enthusiasm and economic ignorance. Despite the misgivings of some in the medical community, doctors largely embraced a public sector health care monopoly model, a monopoly that has only extended its tentacles and its centralising control in the intervening decades. Things are beginning to shift within the medical community, however, and the last two presidents of the Canadian Medical Association have been advocates of the private sector, a sea change of huge proportions. Like the wedding guest in Samuel Taylor Coleridge’s Rime of the Ancient Mariner, they have been traumatized by the brave new world of our health care system and are beginning to draw the policy conclusions that follow from that experience:

He went like one that hath been stunned,
And is of sense forlorn:
A sadder and a wiser man,
He rose the morrow morn.

Words for all of us to ponder on now -- rather than on the forthcoming post-election "morrow morn."


Equity vs. Equality

  • 10.15.2008
Today the Center for Medicine in the Public Interest (CMPI) held a conference entitled, "Physician Disempowerment:  A Transatlantic Malaise."

The opening keynote was Francois Sarkozy, MD (yes, the brother of the other Sarkozy).  Among his provocative comments was the thought that, when it comes to health care "as a right" we need to distinguish "equality from equity."  Further, Dr. Sarkozy discussed the attempts by the French government to reform healthcare by via decreased centralization.  At a time when many here in the US are calling for precisely the reverse, it certainly calls into question the prevailing "SiCKO" mentality of healthcare reform.

Dr. Sarkozy also presented a videotaped interview with the French Minister of Health, Madame Roselyne Bachelot, who spoke on the need for more cooperation between the public and private sectors as well as progams to better empower physicians to deliver the care best care to their patients based on their best medical judgment.

Mais oui!

Swiss physician, Dr. Alphonse Crespo spoke of the "pencil" strike that brought the Swiss healthcare authorities to their knees.  Young physicians and many general practitioners, protesting the healthcare policies of the government, continued to see patients -- but refused to fill out the requisite paperwork.  Talk about cruel and inhuman punishment.

Jacob Arfwedson, CMPI's Paris bureau chief, in a discussin of healthcare technology assessment asked the question, "Is evidence-based medicine at odds with evidence-based policy?"  Hmm.

And much more from the likes of Brian Lee Crowley (Atlantic Institute for Market Studies), Scott Gottlieb (AEI), Michael Weber (CMPI), Harvey Bale (immediate past Director-General of IFPMA), Marc Siegel (CMPI), Gary Applebaum (CMPI), and others.

We will shortly post the complete video proceedings of this event.  Watch this space for further details.



According to PxReporter...

"Developers of companion
diagnostics products, integral to the advancement of personalized medicine, may receive a much-needed financial boost from Congress covering their research and development expenses if a new bill introduced by Rep. Patrick Kennedy (D-RI) passes.
 
The Genomics and Personalized Medicine Act of 2008, H.R.6498, would award “an eligible taxpayer [or test developer] the companion diagnostic test credit” in “an amount equal to the qualified research expenses paid or incurred by the taxpayer during the taxable year, in connection with the development of a qualified companion diagnostic test.”

Not so fast. The credit is offset against any expensing of R&D activities on corporate returns. And the carry forwards on the credits are non-existent as far as I can tell but I am no tax lawyer....

Meanwhile the bill, while well intended, creates new agencies, work groups and layers of review for a personalized diagnostic climb through before it gets approval, thereby adding to costs that can't be claimed under the credit itself.

Are tax credits the only thing pols can come up with to promote innovation?

Why not, for instance, build on the work of the C Path Institute?


"Last October....the C-Path Institute announced that it will use a $2.1 million Arizona state grant to help Ventana take a lung cancer diagnostic through the FDA and standardize a regulatory pathway for companion diagnostics and therapies [see PGx Reporter 10-17-2007].
 
Or support the Critical Path by funding Reagan Udall....

Johns Hopkins University’s Genetics and Public Policy Center’s Gail Javitt notes: “New committees and layers of bureaucracy are proposed when what is needed are concrete steps to enhance oversight and improve laboratory and test quality. …"

Let's hope clearer minds and the Critical Path prevail...

Read More


For those eager to use the current response to the contraction in the credit markets to justify an expanded government role in running health care, there's a difference between injecting capital into the financial system and price controls folks. Capital formation is a result of creating incentives for risk taking and profits. Price controls and redistribution repackaged as "investment" does not have the same effect. The same goes for the claim that a stimulus package that includes more money for Medicaid will help grow the economy. If that was the case, an increase in the murder rate would be a stimulus policy because it would lead to higher spending on trauma care.

Meanwhile the hero of the Far Left -- Hugo Chavez -- provides a preview of how health care will fare under Obama and others in Congress seeking to cut Medicare spending through price controls and rebates:

Read More

Venezuela's oil output slumps under Hugo Chavez

Venezuela's daily oil production has fallen by a quarter since President Hugo Chavez won power, depriving his "Bolivarian Revolution" of much of the benefit of the global boom in oil prices.


1 of 2 Images
A man walks past an anti US graffiti that reads in Spanish 'Gringos out' in Caracas
The US, vilified in a Venezuelan mural, is its best oil customer Photo: AP

To win allies and forge an anti-American front, Mr Chavez sells oil to friendly countries at low prices. Ironically, the only big customer buying Venezuelan oil at the full market price is the United States, which the president routinely denounces as the "Empire".

"As production falls, the sales to the US become more important," said Pietro Donatello, an oil analyst from Latin Petroleum in the capital, Caracas. "Only the US is paying the full amount for Venezuelan oil and in cash, the rest are in some kind of barter agreements."

The state oil company, PDVSA, produced 3.2 million barrels per day in 1998, the year before Mr Chavez won the presidency. After a decade of rising corruption and inefficiency, daily output has now fallen to 2.4 million barrels, according to OPEC figures. About half of this oil is now delivered at a discount to Mr Chavez's friends around Latin America. The 18 nations in his "Petrocaribe" club, founded in 2005, pay Venezuela only 30 per cent of the market price within 90 days, with rest in instalments spread over 25 years.

The other half - 1.2 million barrels per day - goes to America, Venezuela's only genuinely paying customer.

Meanwhile, Mr Chavez has given PDVSA countless new tasks. "The new PDVSA is central to the social battle for the advance of our country," said Rafael Ramirez, the company's president and the minister for petroleum. "We have worked to convert PDVSA into a key element for the social battle."

The company now grows food after Mr Chavez's price controls emptied supermarket shelves of products like milk and eggs. Another branch produces furniture and domestic appliances in an effort to stem the flow of imports. What PDVSA seems unable to do is produce more oil.

Venezuela has proven reserves of 80 billion barrels, but estimates suggest that it may possess 142 billion barrels - more than anywhere else except Saudi Arabia. But the crude is of low quality and must be upgraded before it can be shipped. There are only three upgrade units currently operating, processing only 600,000 barrels per day.

"There is a bottleneck in the Venezuelan production system," said Mazhar al-Sheridah, 68, an oil expert at the Central University of Venezuela. "It will cost at least $32 billion to build another three upgrading units and take some five years, meaning that Venezuelan production is stuck at current levels for a while yet."

All this means that Venezuela has missed much of the benefit from the oil boom and, now that prices are falling, Mr Chavez faces huge financial problems. Nobody is sure at what point his government would be unable to pay its bills, but most sources consulted believe this would probably happen if oil falls to $80 a barrel. Yesterday, oil was trading at $79.80.



 

If you want to see the future of pharma/academe collaboration, then the current edition of Intensive Care Medicine is a must read. The particular issue is the contentious debate over the role of the Eli Lilly & Co. drug, Xigris (drotrecogon alpha/activated – DAA), in severe sepsis.  But there are much larger issues at play.

Interesting Sidebar: The first Xigris Advisory Committee meeting was scheduled for September 12, 2001, but was cancelled for obvious reasons – and the Lilly team had to get back to Indy by bus.  It seems to have been worth the trip. (The rescheduled meeting was held on October 16, 2001 – and it was a lively one.)

Specifically, Lilly is conducting a placebo controlled study of Xigris in patients with septic shock, and the referenced study (PROWESS-shock) must have been a design nightmare given the past controversy -- in addition to the issues involved in conducting such a study while the drug remains commercially available. 

Here is the ICM article, “Design, conduct, analysis and reporting or a multi-national placebo-controlled trial of activated protein C for persistent septic shock.”)

But there are larger issues at play – such as a new model of academia-industry collaboration.  As Jordi Mancebo and Massimo Antonelli write in their ICM editorial:

“This month’s issue of the Journal contains a somewhat unusual article and two accompanying editorials.  The authors of the article are members of the steering committee of an on-going Eli Lilly trial on activated protein C for persistent septic shock.  They describe a number of steps that have been adopted in order to ensure transparency in disclosing financial conflicts, facilitate comprehension and interpretation of results, minimize possible risks, and maximize eventual benefits for patientsThis approach constitutes a new model of academia-industry collaboration.

It’s also important to note that the academic steering committee will oversee not only the conduct of the trial (nothing new there) but will also write the study manuscripts.

Further on Mancebo and Antonelli write:

“The novelty here is the full disclosure of the process by which this study was designed, and a description of how it will be conducted, analyzed and reported.”

In a second ICM editorial, Peter M. Suter and Jukka Takala write about to who benefits from this “new model”:

“The primary objectives of each of the three stakeholders are quite different.  The pharmaceutical industry wants to make profit, but is also very much interested in bringing new products to the market (necessary for its sustainable development) and in innovation (which improves its image in the eyes of society).  Science is curiosity-driven, with the aim of furthering our understanding of human biology, physiology and mechanisms of disease, also to discover better ways to treat disease.  Finally, the objective of medicine is to help patients to get better quickly and to recover a good quality of life.”

Suter and Takala conclude:

“The investigators of the PROWESS-shock trial have made a laudable effort to introduce an improved model of collaboration between science, medicine and industry.  This approach could help to get us out of the image of a Bermuda triangle, where benefits of research and resources for health care disappear in a black hole or the wallets of a few.”

(This is the same Peter Suter who once said he wouldn’t give his own brother -- who had septic shock -- Xigris.)

As Mancebo and Antonelli write, “We welcome this unprecedented step forward.”

Amen.

Parallel-o-gram

  • 10.10.2008

According to the Financial Times:

“Drug distributors who arbitrage the price differences across the European Union could see their €4bn ($5.5bn) a year trade severely curtailed under proposed legislation set to be unveiled by the European Commission later this month. A document obtained by the FT includes rules to crack down on the trade in counterfeit medicines that would make it difficult for wholesalers legally to move pharmaceuticals across the EU's open borders. New rules would put tight restrictions on the repackaging of medicines, a process required to ensure the correct language and coding information is used on packaging and information leaflets.”

“The repackaging controls, drafted for Günther Verheugen, EU trade and industry commissioner, as part of broader reforms to laws governing the pharmaceutical sector, have been justified as a way to reduce the threat of counterfeit medicines, which the pharmaceutical industry says is a growing danger to patients' health.”

On the other side of the issue, Heinz Kobelt, secretary-general of the European Association of Euro-Pharmaceutical Companies, which represents parallel traders, said the Commission had been unable to provide any evidence that parallel traders had allowed counterfeit prescription medicines to enter the pharmacy chain.

Heinz has a very selective memory.

Earlier this year, at a London policy conference on parallel trade (where we both spoke), Heinz pointed out (correctly) that the recent spate of counterfeit drugs that had infiltrated legitimate UK pharmacies had been discovered by a parallel trader. And that’s true. But what he didn’t mention (and seems to have again conveniently forgotten) is that those same products had already passed through three other parallel traders without being found.

Oops.

According to a new survey, “Millennial” voters (18-28 years old) -- often are portrayed as the new “driving force” in American politics -- place health care reform fifth on their list of electoral issue priorities (behind the economy, energy/gas prices, jobs/unemployment, and Iraq). But, when millennial voters are engaged on the issue of health care reform they have some very strong – and often contradictory – opinions about reform -- particularly when it comes to issue of “universal care.”

The Center for Medicine in the Public Interest (the public policy institute home of www.drugwonks.com) has just released a new survey of millennial views on health care reform. The national public opinion poll of young voters demonstrates limited acceptance for the potential consequences of greater government control over health care.

While millennial voters report to strongly support the need for reform and the concept of “universal care,” when asked if they are willing to pay higher taxes to pay for a government-run health care system, their level of support swiftly turns in the opposite direction.

Millennial voters are strongly against government-care that results in longer wait times to see a health care provider, limits to the types of treatments and medicines they can access, and the potential for the government to interfere in the decision making and relationship between doctor and patient.

Some germane findings:

* A majority (75 percent) of millennials were concerned about their current and future ability to access affordable health care

* Eighty-three percent of millennials believe that America’s health care system is in need of reform and that health care insurance should be available to all Americans; and,

 

* Seven in ten millennials support the creation of a new government program to manage and administer public health insurance coverage options, and 6 in 10 were okay with increasing government spending to support health care reforms.

However, as the potential cost of health care reform was shifted directly onto individuals and not the government the level of support for reform ideas also shifted among millennial voters.

* A majority (51 percent) were not in support of any health care reforms thatcould raise their personal tax burden;

 

* Sixty-two percent said they would not support any health care reforms that could increase wait-times to see a doctor or the availability of treatments and medicines; and,

* Millennial voters were also equally unsupportive (62 percent) of health care reforms that would increase the role of the government regulation and oversight in doctor-patient decision-making.

This healthcare “idealism gap” among millennial voters speaks to a large divide between what this group is hearing from politicians and pundits -- and what they are willing to accept. This insight into how younger voters think and feel about these healthcare reform shows that all sides of the debate need to do a better job educating this important voting bloc about how various reform plans will impact the future of medicine in America.”

For further details please go to www.biggovhealth.org.

This poll is the result of 1001completed interviews with adults 18-28 years of age who are registered to vote.  Respondents were selected at random from the 48 contiguous states.  The interviews were conducted between September 12th, 2008 and September 20th, 2008. The margin of error for this study is ± 3.09 percentage points at the 95% confidence level. Interviews were monitored at random. 

Sampling for this study was conducted using a national probability sample of all exchanges and area codes across the 48 contiguous States.  All interviews were conducted using a computer assisted telephone interviewing system.  Statistical weights were designed from the United States Census Bureau statistics.

 

Suppose that a new study about an "intervention" showed that those exposed had a 50% likelihood of emotional exhaustion and depersonalization, with 11% occurrence of suicidal ideation. Those figures are frightening at face value - and were it a new drug associated with those findings. One would expect both FDA restrictive actions and congressional hearings to be likely responses.
 
In fact, those observations were reported last month in the Annals of Internal Medicine (149: 334) by Dyrbye and colleagues - their article was entitled "Burnout and suicidal ideation among U.S. Medical Students". This publication was based on a survey of students about the phenomenon of burnout and related concerns, with several interesting outcomes of potential utility for school administrators. 
 
For purposes of this discussion, it is tempting to speculate that a "proportionate response" for these findings of medical student risks and those of similar "side effects" from a drug would not be contemplated...... can you picture "recalls" and closures of med students programs until the risks were better understood and improved detection and management practices put in place? It's also interesting to look at the relative inattention of the lay media to this study as a puzzling juxtaposition to the amplification of any new drug safety report (regardless of validation), for findings of much lesser magnitude..... certainly, young doctors are not viewed by the press as merely "necessary fodder" for the war against disease. But some alternate explanation for their silence on this matter is not clear.
 
Having been a survivor of medical training "last century" during a time when on call hours and similar demands were likely more onerous than at present, it comes as no surprise that health care occupations with high stress job content can be challenging at best and threatening at worst; such conditions deserve more careful attention by training programs (beyond just having applicants sign informed consents that "med school may be hazardous to my health").
 
If one searches for root causes to the apparently disparate reaction to suicidality findings from drugs versus stress, it is possible that, similar to lay public understanding of diseases, the perception of dread is inversely proportionate to actual risk - people tend to fear that which we do not fully comprehend and do not believe we can control - and respond disproportionately. This skewed observational bias is also documented in public views of the actual versus perceived risk of hepatitis vs. AIDS, and in the proportionate attention given in the press to what is dreaded vs. truly threatening.
 
Perhaps current efforts by regulators and industry to provide more balanced attention to benefit-risk considerations will pave the future path to uniformly tempered responses to any new findings with drugs or other factors; until that time, our public health policy views will continue to be whip-sawed by amplification of every isolated factoid out of context - let's all endeavor to model that kind of balance going forward.

The depths to which Barack Obama stooped to distance himself from the elements of his own health care proposal was astounding. No mandates or taxes on small businesses? No price controls on insurance companies (just making sure they pay their claims and cover what they say they cover)? I won't even go into the distortion of the claim that McCain proposes "eliminating" state regulation of insurance companies any more than Obama does by setting up a national marketplace.

Then he keeps on claiming he can reduce premiums by $2500. An exaggeration that is on the verge of a lie... Half of that is supposed to come from costs generated fromo electronic health records! But his estimate of "savings" from EHRs is based on productivity gains which themselves are estimates drawn from private sector examples in the auto industry over ten years. The other amount comes from "disease managment" savings achieved by getting doctors to practice guideline driven medicine. That's called rationing. Also unlikely. And even David Cutler, one of the smartest health care analysts in America acknowledges that the $2500 doesn't translate into reduce premiums:

Obama health adviser Cutler confirmed that the campaign's $2,500 per family projection doesn't represent only out-of-pocket savings for individual Americans. It includes savings to the government, employers and insurers, savings that could, Cutler says, trickle down to families in the form of lower taxes, higher wages or reduced premiums. In fact, Cutler says the $2,500 figure simply comes from dividing an overall savings estimate that's somewhat larger than $120 billion by an approximate number of four-person families in the U.S. "[W]e take the total and divide by the total population, then consider a 4 person family,"

Read More


CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog